文献速递心脑血管急症重症综合管理与镇静镇痛

利伐沙班用于心力衰竭、窦性心律及冠心病患者

Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease.
PubMed 文献 · N Engl J Med · 2018-08-27
一句话结论在慢性心衰加重、LVEF≤40%、冠心病且无房颤的患者中,利伐沙班2.5 mg每日两次未显著降低死亡、心梗或卒中复合终点(HR 0.94,95%CI 0.84–1.05,P=0.27)。

COMMANDER HF为双盲随机试验,纳入5022例慢性心衰、LVEF≤40%、冠心病、利钠肽升高且无房颤的患者,在因心衰加重住院治疗后随机接受利伐沙班2.5 mg每日两次或安慰剂。中位随访21.1个月,主要疗效终点(全因死亡、心梗或卒中)在利伐沙班组发生率为25.0%,安慰剂组为26.2%,无显著差异(HR 0.94,95%CI 0.84–1.05,P=0.27)。全因死亡率两组分别为21.8%与22.1%(HR 0.98,95%CI 0.87–1.10),主要安全终点(致命性出血或关键部位出血)分别为18例与23例(HR 0.80,95%CI 0.43–1.49,P=0.48)。该研究不支持在该人群中常规使用利伐沙班以预防血栓事件。

要点

  • 在慢性心衰加重、LVEF≤40%、冠心病且无房颤的患者中,利伐沙班2.5 mg每日两次较安慰剂未显著降低全因死亡、心梗或卒中复合终点(25.0% vs 26.2%,HR 0.94,95%CI 0.84–1.05,P=0.27)。
  • 全因死亡率在利伐沙班组为21.8%,安慰剂组为22.1%,无显著差异(HR 0.98,95%CI 0.87–1.10)。
  • 主要安全终点(致命性出血或关键部位出血)利伐沙班组18例,安慰剂组23例(HR 0.80,95%CI 0.43–1.49,P=0.48)。
  • 研究人群为慢性心衰、LVEF≤40%、冠心病、利钠肽升高且无房颤,并在心衰加重治疗后入组。
  • 中位随访21.1个月,利伐沙班2.5 mg每日两次未显著改善主要疗效终点。

适用人群与场景

  • 慢性心力衰竭患者,左心室射血分数≤40%,合并冠状动脉疾病,血浆利钠肽浓度升高,且无房颤,在因心衰加重接受治疗后入组。

处置流程与药物剂量

  • 利伐沙班组:在标准治疗基础上给予利伐沙班2.5 mg每日两次口服。
  • 对照组:在标准治疗基础上给予安慰剂。

研究设计与关键结果

  • 双盲随机试验,纳入5022例慢性心衰、LVEF≤40%、冠心病、利钠肽升高且无房颤的患者,随机接受利伐沙班2.5 mg每日两次(2507例)或安慰剂(2515例)。
  • 主要疗效终点(全因死亡、心梗或卒中)利伐沙班组626例(25.0%),安慰剂组658例(26.2%),HR 0.94(95%CI 0.84–1.05),P=0.27。
  • 全因死亡率利伐沙班组21.8%,安慰剂组22.1%,HR 0.98(95%CI 0.87–1.10)。
  • 主要安全终点(致命性出血或关键部位出血导致永久残疾)利伐沙班组18例,安慰剂组23例,HR 0.80(95%CI 0.43–1.49),P=0.48。
  • 中位随访21.1个月。

证据类型、等级与局限

  • 证据类型:双盲随机对照试验(COMMANDER HF,NCT01877915)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于慢性心衰加重、LVEF≤40%、冠心病且无房颤的患者,利伐沙班2.5 mg每日两次未显著降低死亡、心梗或卒中复合终点,不支持在该人群中常规使用以预防血栓事件。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Heart failure is associated with activation of thrombin-related pathways, which predicts a poor prognosis. We hypothesized that treatment with rivaroxaban, a factor Xa inhibitor, could reduce thrombin generation and improve outcomes for patients with worsening chronic heart failure and underlying coronary artery disease.

METHODS: In this double-blind, randomized trial, 5022 patients who had chronic heart failure, a left ventricular ejection fraction of 40% or less, coronary artery disease, and elevated plasma concentrations of natriuretic peptides and who did not have atrial fibrillation were randomly assigned to receive rivaroxaban at a dose of 2.5 mg twice daily or placebo in addition to standard care after treatment for an episode of worsening heart failure. The primary efficacy outcome was the composite of death from any cause, myocardial infarction, or stroke. The principal safety outcome was fatal bleeding or bleeding into a critical space with a potential for causing permanent disability.

RESULTS: Over a median follow-up period of 21.1 months, the primary end point occurred in 626 (25.0%) of 2507 patients assigned to rivaroxaban and in 658 (26.2%) of 2515 patients assigned to placebo (hazard ratio, 0.94; 95% confidence interval [CI], 0.84 to 1.05; P=0.27). No significant difference in all-cause mortality was noted between the rivaroxaban group and the placebo group (21.8% and 22.1%, respectively; hazard ratio, 0.98; 95% CI, 0.87 to 1.10). The principal safety outcome occurred in 18 patients who took rivaroxaban and in 23 who took placebo (hazard ratio, 0.80; 95% CI, 0.43 to 1.49; P=0.48).

CONCLUSIONS: Rivaroxaban at a dose of 2.5 mg twice daily was not associated with a significantly lower rate of death, myocardial infarction, or stroke than placebo among patients with worsening chronic heart failure, reduced left ventricular ejection fraction, coronary artery disease, and no atrial fibrillation. (Funded by Janssen Research and Development; COMMANDER HF ClinicalTrials.gov number, NCT01877915 .).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Zannad F, Anker SD, Byra WM, et al. Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease. N Engl J Med. 2018. PMID: 30146935. doi:10.1056/NEJMoa1808848

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。